Background: The views regarding the associations between metformin use and hepatocellular carcinoma (HCC) among diabetes mellitus (DM) patients are divisive. Thus we summarized all available published studies evaluating the relationship between metformin therapy and HCC survival and risk, and aim to conduct an updated meta-analysis study to more accurately clarify the association.
Methods: We searched for articles regarding impact of metformin use on risk and mortality of HCC in DM and published before April 2021 in databases (PubMed and Web of Science). We used STATA 12.0 software to compute odds ratios (ORs)/relative risks (RRs) or hazard ratios (HRs) and their 95% confidence intervals (CIs) to generate a computed effect size and 95% CI.
Results: The present study showed that metformin use was associated with a decreased risk of HCC in DM with a random effects model (OR/RR = 0.59, 95% CI 0.51-0.68, I2 = 96.5%, p < 0.001). In addition, the study indicated that metformin use was associated with a decreased all-cause mortality of HCC in DM with a random effects model (HR = 0.74, 95% CI 0.66-0.83, I2 = 49.6%, p = 0.037).
Conclusion: In conclusion, our studies support that the use of metformin in DM patients is significantly associated with reduced risk and all-cause mortality of HCC. And more prospective studies focusing on the metformin therapy as a protective factor for HCC are needed to verify the accuracy of the findings.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clinre.2021.101781 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Diabetes is known to cause cognitive impairments and synaptic dysfunction. This study investigates the effects of (EO), (CT), Vitamin C, and metformin on cognitive function and synaptic density (SYN) in diabetic rats. This work aims to evaluate the impact of various treatments on spatial learning, memory, and SYN in a diabetic rat model.
View Article and Find Full Text PDFSafety and Efficacy of Metformin for Idiopathic Intracranial Hypertension. A U.S-Based Real-World Data Retrospective Multicenter Cohort Study.
ASIDE Intern Med
December 2024
Montefiore-Einstein Cerebrovascular Research Lab, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Introduction: Managing idiopathic intracranial hypertension (IIH) is challenging due to limited treatment options. This study evaluates metformin as a potential therapy for IIH, examining its impact on disease outcomes and safety.
Methods: We performed a retrospective cohort study using the TriNetX database, covering data from 2009 to August 2024.
Unveiling the impacts of metformin on hepatocellular carcinoma: A bioinformatic exploration in cell lines.
Narra J
December 2024
Department of Histology, Faculty of Medicine, Universitas Riau, Pekanbaru, Indonesia.
The most common type of liver cancer is hepatocellular carcinoma (HCC), accounting for 75-85% of cases. Despite its associated side effects, sorafenib remains the standard treatment for HCC. Given the critical need to improve therapeutic efficacy while minimizing adverse effects, alternative drugs must be thoroughly investigated.
View Article and Find Full Text PDFMetformin's impact on asprosin and FBN1 expression: Potential mechanisms beyond insulin sensitivity in type 2 diabetes in rats.
Curr Res Pharmacol Drug Discov
December 2024
Pregnancy Health Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.
Background: Asprosin, a novel adipokine released under fasting conditions, may play a significant role in the pathophysiology of type 2 diabetes mellitus (T2DM). The objective of this study is to investigate the effects of metformin on serum asprosin levels and FBN1 gene expression in white adipose tissue in male rats.
Methods: Thirty-two male Wistar rats were randomly and equally divided into four groups (n = 8): 1.
[Impacts of curcumin on proliferation, migration and cisplatin resistance of bladder cancer cells by regulating LKB1-AMPK-LC3 signaling pathway].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
January 2025
National Key Laboratory of Bioreactors, School of Biological Engineering, East China University of Science and Technology, Shanghai 200237, China. *Corresponding author, E-mail:
Article Synopsis
- The study investigates how curcumin affects bladder cancer cells regarding growth, movement, and resistance to cisplatin (a chemotherapy drug) by targeting a specific signaling pathway (LKB1-AMPK-LC3).
- Human bladder cancer cells (T24) and their cisplatin-resistant counterparts (T24/DDP) were treated with varying concentrations of curcumin, and various assays measured cell proliferation, migration, autophagy, and apoptosis.
- Results showed that curcumin, especially when combined with metformin, influences these cellular functions and could reduce drug resistance, affecting the expression of proteins in the targeted signaling pathway.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!